奥扎格雷钠联合疏血通治疗急性脑梗死的疗效评价及对血清TNF-a、IL-6和hs-CRP水平的影响

Evaluation of the efficacy of sodium ozagrel combined with Shuxuetong injection in the treatment of acute cerebral infarction and their effect on serum TNF-α, IL-6 and hs-CRP levels

目的 :探究奥扎格雷钠联合疏血通治疗急性脑梗死的临床疗效及对患者血清TNF-a、IL-6和hs-CRP水平的影响。方法 :回顾性分析2013年1月—2015年6月我院收治的急性脑梗死患者72例,根据治疗方式的不同,分为研究组38例和对照组34例。对照组给予脱水降压、抗血小板凝聚、脑细胞保护及对症支持等常规治疗及奥扎格雷氯化钠注射液治疗,研究组在对照组的基础上加用疏血通注射液。比较两组患者的临床疗效、不良反应以及治疗前后血清TNF-a、IL-6和hs-CRP水平的变化。结果 :研究组治疗的总有效率和ADL评分为84.21%和(78.43±8.75)分,对照组为67.64%和(66.54±10.12)分(P<0.05);研究组治疗7 d、14 d后血清TNF-α、IL-6及hs-CRP的含量分别为(2.21±0.36)ng/L和(1.86±0.44)ng/L、(54.75±3.25)pg/L和(42.36±3.62)pg/L及(7.53±3.22)mg/L和(3.19±1.90)mg/L,而对照组分别为(2.63±0.42)ng/L和(2.14±0.39)ng/L、(60.61±3.69)pg/L和(55.73±3.16)pg/L及(10.46±3.41)mg/L和(6.23±2.94)mg/L(P<0.05)。结论 :奥扎格雷钠联合疏血通治疗急性脑梗死疗效确切,不良反应少,且还能显著降低急性脑梗死患者血清TNF-a、IL-6和hs-CRP水平,抑制患者机体内的炎症反应。

Objective： To explore the clinical efficacy of sodium ozagrel combined with Shuxuetong injection in the treatment of acute cerebral infarction and their effect on serum TNF-α, IL-6 and hs CRP levels. Methods： Seventy-two cases of patients with acute cerebral infarction were retrospectively analyzed and divided into a study group （38 cases） and a control group （34 cases） based on the differences of the treatment methods. The control group was treated by conventional treatments including dehydration, ant^hypertension, anti-platelet aggregation, protection of brain cells, symptomatic and supportive treatment and ozagrel while the study group with Shuxuetong injection on the basis of the control group. The clinical efficacy and adverse reactions and the changes of serum TNF-α, IL-6 and hs-CRP levels were compared between two groups. Results： The total effective rate and ADL scores were 84.21% and （78.43 ＋ 8.75） in the study group and 67.64% and （66.54±10.12） in the control group （P〈0.05）. The contents of serum TNF-α lpha, IL-6 and hs-CRP were （2.21±0.36） ng/L and （1.86±0.44）, （54.75±3.25） pg/L and （42.36±3.62） pg/L as well as （7.53±3.22） mg/L and （3.19±1.90） mg/L in the study group and （2.63±0.42） ng/L and （2.14±0.39） ng/L, （60.61±3.69） pg/L and （55.73±3.16） pg/L as well as （10.46±3.41） mg/L and （6.23±2.94） mg/L in the control group 7 and 14 days after treatment, respectively （P〈0.05）. Conclusion： The clinical efficacy of sodium ozagrel combined with Shuxuetong injection in the treatment of acute brain infarction is clear. They possess less adverse reactions and can significantly reduce the serum TNF-α, IL-6 and hs-CRP levels and inhibit the inflammatory reaction in patients.